Bone Marrow Cancer Drug of Australia’s Cytopia Shows Promise
This article was originally published in PharmAsia News
Executive Summary
Australian biotech Cytopia Research's CYT387 drug for fighting a cancer-cell mutation associated with myeloproliferative disorders of the bone marrow has demonstrated efficacy in mouse studies. Researchers heading the Cytopia-funded study found the drug blocks the enzyme that causes the disorders and could become the first U.S.-approved drug targeting the major MPD bone-marrow cancers. The head researcher said there is a good chance of entering clinical trials next year with the drug, an inhibitor of the JAK-2-V617F enzyme. The three major MPDs are polyeythemia vera, essential thrombocythemia and primary myelofibrosis. (Click here for more